Requirement for p38 and p44/p42 mitogen-activated protein kinases in RAGE-mediated nuclear factor-κB transcriptional activation and cytokine secretion

Diabetes

Volumn 50, Issue 6, 2001, Pages 1495-1504

  Yeh, Chen Hsiung ^a   Sturgis, Lydia ^a   Haidacher, Joe ^a   Zhang, Xue Nong ^a   Sherwood, Sidney J ^a   Bjercke, Robert J ^a   Juhasz, Ondrej ^b   Crow, Michael T ^b   Tilton, Ronald G ^a   Denner, Larry ^a  

^a TEXAS BIOTECHNOLOGY CORPORATION   (United States)

^b NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 6 N CARBOXYMETHYLLYSINE; ACETYLCYSTEINE; ADVANCED GLYCATION END PRODUCT RECEPTOR; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; REACTIVE OXYGEN METABOLITE; SERUM ALBUMIN; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA;

AGING; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DIABETES MELLITUS; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; INFLAMMATION; KIDNEY FAILURE; MONOCYTE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REPORTER GENE; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

EID: 0034987093     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.50.6.1495     Document Type: Article

References (60)

1. Advanced protein glycosylation in diabetes and aging
2. Advanced glycosylation: Chemistry, biology, and implications for diabetes and aging
3. Pathogenic effects of advanced glycosylation: Biochemical, biologic, and clinical implications for diabetes and aging
4. Cell activation by glycated proteins: AGE receptors, receptor recognition factors and functional classification of AGEs
5. Activation of receptor for advanced glycation end products: A mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis
6. RAGE mediates a novel proinflammatory axis: A central cell surface receptor for S100/calgranulin polypeptides
7. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease
8. Amyloid beta 2-microglobulin is modified with N epsilon(carboxymethyl)lysine in dialysis-related amyloidosis
9. Recent progress in advanced glycation end products and diabetic complications
10. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy
11. Aminoguanidine ameliorates albuminuria in diabetic hypertensive rats
12. Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface
13. Two novel rat liver membrane proteins that bind advanced glycosylation endproducts: Relationship to macrophage receptor for glucose-modified proteins
14. Molecular identity and cellular distribution of advanced glycation endproduct receptors: Relationship of p60 to OST-48 and p90 to 80K-H membrane proteins
15. Molecular identity and cellular distribution of advanced glycation endproduct receptors: Relationship of p60 to OST-48 and p90 to 80K-H membrane proteins
16. Antibacterial activity of lysozyme and lactoferrin is inhibited by binding of advanced glycation-modified proteins to a conserved motif
17. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins
18. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues
19. Cellular receptors for advanced glycation end products: Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions
20. The dark side of glucose
21. The receptor for advanced glycation end products (RAGE) is a central mediator of the interaction of AGE-β2 microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway: Implications for the pathogenesis of dialysis-related amyloidosis
22. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy: Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats
23. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts
24. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins
25. Identification of binding sites for transcription factors NF-κB and AP-2 in the promoter region of the human heme oxygenase 1 gene
26. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice: A potential mechanism for the accelerated vasculopathy of diabetes
27. Advanced glycation end product (AGE)-mediated induction of tissue factor in cultured endothelial cells is dependent on RAGE
28. Molecular mechanisms of diabetic angiopathy: Clues for innovative therapeutic interventions
29. Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products
30. Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress
31. Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions: Implication for glycoxidative stress in the pathogenesis of diabetic nephropathy
32. Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging
33. N(epsilon)-(carboxymethyl) lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression
34. N (epsilon)-(carboxymethyl)lysine protein adduct is a major immunological epitope in proteins modified with advanced glycation end products of the Maillard reaction
35. Preparation of human mononuclear cell populations and subpopulations
36. The human prointerleukin 1 beta gene requires DNA sequences both proximal and distal to the transcription start site for tissue-specific induction
37. Rapid detection of octamer binding proteins with "mini-extracts," prepared from a small number of cells
38. An essential role for NF-κB in preventing TNF-α-induced cell death
39. NF-κB activation provides the potential link between inflammation and hyperplasia in the arthritic joint
40. High molecular weight hyaluronic acid inhibits advanced glycation endproduct-induced NF-κB activation and cytokine expression
41. Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-κB require the cytoplasmic domain of the receptor but different downstream signaling pathways
42. Effect of advanced glycation end product-modified albumin on tissue factor expression by monocytes: Role of oxidant stress and protein tyrosine kinase activation
43. Protein tyrosine phosphorylation in leukocyte activation through receptors for IgG
44. Fcγ receptor-mediated mitogen-activated protein kinase activation in monocytes is independent of Ras
45. Tyrosine phosphorylation of Cbl upon epidermal growth factor (EGF) stimulation and its association with EGF receptor and downstream signaling proteins
46. Inhibition of platelet-derived growth factor and epidermal growth factor receptor signaling events after treatment of cells with specific synthetic inhibitors of tyrosine kinase phosphorylation
47. Advanced glycation endproducts stimulate mitogen-activated protein kinase and proliferation in rabbit vascular smooth muscle cells
48. Advanced glycation endproducts stimulate the MAP-kinase pathway in tubulus cell line LLC-PK1
49. Characterization of the structure and function of the fourth member of p38 group mitogen-activated protein kinases, p38δ
50. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases
51. Is NF-κB the sensor of oxidative stress?
52. Iκ-Bα degradation and nuclear factor-κB DNA binding are insufficient for interleukin-1β and tumor necrosis factor-α-induced κB-dependent transcription: Requirement for an additional activation pathway
53. Activation of transcription factor NF-κB and p38 mitogen-activated protein kinase is mediated by distinct and separate stress effector pathways
54. The p38 mitogen-activated protein kinase is required for NF-κB-dependent gene expression: The role of TATA-binding protein (TBP)
55. P38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways are required for nuclear factor-αB p65 transactivation mediated by tumor necrosis factor
56. P38 mitogen-activated protein kinase inhibitors: Mechanisms and therapeutic potentials
57. p38 MAPK signalling cascades in inflammatory disease
58. Inhibitors of p38 MAP kinase: Therapeutic intervention in cytokine-mediated diseases
59. p38 MAPK inhibition decreases TNF-α production and enhances postischemic human myocardial function
60. Technical note: The serum concentration of the advanced glycation endproduct N epsilon-(caxboxymethyl)lysine is increased in uremia